Vaxcyte, Inc. 4

Vaxcyte President and CFO Andrew Guggenhime surrendered 7,155 shares of common stock to cover taxes upon RSU vesting while retaining substantial direct and indirect holdings.

On September 8, 2026, Andrew Guggenhime, President and CFO of Vaxcyte, Inc., had 7,155 shares of common stock withheld by the company at an implied price of approximately $60.36 per share, for an estimated value of about $432,000, to satisfy tax withholding obligations upon the vesting of previously granted RSUs. This Form 4 reflects a tax-related disposition classified under transaction code “F,” rather than an open-market sale, and thus is generally viewed as routine equity compensation administration. Following the transaction, Guggenhime reported direct ownership of 95,316 shares and indirect ownership of 61,850 shares of common stock held through ALG 2025 GRAT HOLDINGS LLC, where he is the annuitant and trustee of the owning grantor retained annuity trust.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001230724-26-000018

Alert Tier

5